Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819091 · ClinicalTrials.gov registry record · Phase 3
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT00819091 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Boehringer Ingelheim. The registered enrollment target is 245 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00819091, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BI 1356
Study Locations (20)
Other
- 1218.35.54003 Boehringer Ingelheim Investigational Site - Capital Federal
- 1218.35.54005 Boehringer Ingelheim Investigational Site - Corrientes
- 1218.35.54001 Boehringer Ingelheim Investigational Site - Mar del Plata
- 1218.35.54006 Boehringer Ingelheim Investigational Site - Parque Velez Sarfield
- 1218.35.36001 Boehringer Ingelheim Investigational Site - Budapest
- 1218.35.36002 Boehringer Ingelheim Investigational Site - Budapest
- 1218.35.36004 Boehringer Ingelheim Investigational Site - Budapest
California
- 1218.35.10001 Boehringer Ingelheim Investigational Site - Los Angeles
- 1218.35.10016 Boehringer Ingelheim Investigational Site - National City
Florida
- 1218.35.10017 Boehringer Ingelheim Investigational Site - Fort Lauderdale
- 1218.35.10021 Boehringer Ingelheim Investigational Site - Fort Lauderdale
Texas
- 1218.35.10009 Boehringer Ingelheim Investigational Site - Dallas
- 1218.35.10019 Boehringer Ingelheim Investigational Site - Sugar Land
Alabama
- 1218.35.10002 Boehringer Ingelheim Investigational Site - Birmingham
Illinois
- 1218.35.10013 Boehringer Ingelheim Investigational Site - Chicago
Michigan
- 1218.35.10015 Boehringer Ingelheim Investigational Site - Flint
North Carolina
- 1218.35.10018 Boehringer Ingelheim Investigational Site - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819091
The ClinicalTrials.gov registry entry for NCT00819091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00819091 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00819091 about?
NCT00819091 is a clinical study titled "Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug". Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
What is the current status of trial NCT00819091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2008-12.
What conditions does trial NCT00819091 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00819091?
The interventions under investigation include: Placebo (DRUG), BI 1356 (DRUG).
Who is sponsoring clinical trial NCT00819091?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00819091 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.